A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban
Clinical trial NCT02220725 · COMPLETED
Trial details
- NCT number
- NCT02220725
- Sponsor
- Portola Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-05-01
- Primary completion
- 2015-08-01
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.